Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chief Executive Officer and Chief Science Officer, presides over the opening bell to celebrate the company's 10 year listing anniversary. He is joined by members of the Progenics management team.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of Human Immunodeficiency Virus (HIV) infection and cancer. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation (oral and subcutaneous formulations) and post-operative ileus (intravenous formulation). In March 2007, the Company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the subcutaneous formulation of methylnaltrexone for patients experiencing opioid-induced constipation while receiving palliative care, followed in May 2007 by Wyeth's submission of a Marketing Authorization Application (MAA) in Europe to the European Medicines Agency (EMEA).

The Prescription Drug User Fee Act (PDUFA) date for the subcutaneous methylnaltrexone New Drug Application (NDA) is January 30, 2008. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV entry co-receptor CCR5, which has completed phase 1b clinical studies with positive results. The Company is developing innovative therapies for prostate cancer, including a human monoclonal antibody to prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing therapeutic vaccines designed to stimulate an immune response to PSMA.

For more information, please visit PGNX's web site at www.progenics.com.

Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at jolene.libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission.

For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at rob.tannenbaum@nasdaq.com.

© Copyright 2007, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.

Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search